Pancreatic Ductal Adenocarcinoma
270
79
120
60
Key Insights
Highlights
Success Rate
67% trial completion
Published Results
26 trials with published results (10%)
Research Maturity
60 completed trials (22% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
11.1%
30 terminated out of 270 trials
66.7%
-19.9% vs benchmark
4%
11 trials in Phase 3/4
43%
26 of 60 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 60 completed trials
Clinical Trials (270)
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers
Tissue Adhesive Glue Modified Cyanoacrylate (Glubran® 2) in Soft Pancreas
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
Pancreatic Cancer Detection Consortium
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
UCSF PANC Cyst Registry
A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary Cancers
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Utility of ctDNA in Early Switch of First-line Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma